(1) No person may
possess or use a drug, substance or medication on the premises of a facility
under the jurisdiction of the Commission for which:
(a) a recognized analytical method has not
been developed to detect and confirm the administration of such
substance;
(b) the use of which may
endanger the health and welfare of the horse or endanger the safety of the
driver;
(c) the use of which may
adversely affect the integrity of racing; or
(d) no generally-accepted use in equine care
exists.
(2)
Prohibited Substances and Methods.
(a) The substances and methods listed in the
annexed Prohibited List may not be used at any place or time, and may not be
possessed on the premises of a racing or training facility under the
jurisdiction of the Commission, except as a restricted therapeutic
use.
(b)
Restricted
Therapeutic Use. A limited number of medication on the Prohibited
List shall be exempted when the administration occurs in compliance with the
annexed Required Conditions for Restricted Therapeutic Use:
1. Report When Sampled means the
administration of the substance must be reported to the Commission when the
horse is next sampled, if the horse is sampled within 24 hours after the
administration;
2. Pre-file
Treatment Plan means that if the Commission where the horse is located requires
the filing of treatment plans, then a treatment plan for the substance must be
filed by the time of administration in a manner approved by such
Commission;
3. Written Approval
from Commission means the Commission has granted written approval of a written
treatment plan before the administration of the substance;
4. Emergency Use (report) means the substance
had to be administered due to an acute emergency involving the life or health
of the horse, provided the emergency use is reported to the Commission as soon
as practicable after the treatment occurs;
5. Prescribed by Veterinarian means the
substance has been prescribed by an attending veterinarian, in compliance with
ARCI 011-010 Veterinary Practices, and recorded in the
veterinary records in the manner required by the Commission;
6. Report Treatment means the treatment must
be reported to the Commission by the trainer at the time of administration to
provide the Commission with information for the Veterinarian's List. The
trainer may delegate this responsibility to the treating veterinarian, who
shall make the report when so designated; and
7. Other Limitations means additional
requirements that apply, such as a substance may be used in only fillies or
mares or a horse that is administered a substance shall be reported immediately
to the Commission and placed on the Veterinarian's List for a specific minimum
period of time. The use of the substance must comply with other applicable
rules of the Commission.
(c) No person shall at any time administer
any other doping agent to a horse except pursuant to a valid therapeutic,
evidence-based treatment plan.
1. Other
doping agent means a substance that is not listed in the annexed Prohibited
List, has a pharmacologic potential to alter materially the performance of a
horse, has no generally accepted medical use in the horse when treated, and is:
a. capable at any time of causing an action
or effect, or both, within one or more of the blood, cardiovascular, digestive,
endocrine, immune, musculoskeletal, nervous, reproductive, respiratory, or
urinary mammalian body systems; including, but not limited to, endocrine
secretions and their synthetic counterparts, masking agents, oxygen carriers,
and agents that directly or indirectly affect or manipulate gene expression;
but
b. not a substance that is
considered to have no effect on the physiology of a horse except to improve
nutrition or treat or prevent infections or parasite infestations.
2. The Commission may publish
advisory warnings that certain substances or administrations may constitute a
violation of 205 CMR 3.28.
3.
Therapeutic, evidence-based treatment plan means a planned course of treatment
written and prescribed by an attending veterinarian before the horse is treated
that:
a. describes the medical need of the
horse for the treatment, the evidence-based scientific or clinical
justification for using the doping agent, and a determination that recognized
therapeutic alternates do not exist; and
b. complies with ARCI 011-010
Veterinary Practices, meets the standards of veterinary
practice of the jurisdiction, and is developed in good faith to treat a medical
need of the horse.
4.
Such plans shall not authorize the possession of a doping agent on the premises
of a racing or training facility under the jurisdiction of the
Commission.
(3)
The possession and/or use of the following substances or of blood doping
agents, including but not limited to those listed in 205 CMR 3.28(3)(a) through
(j), on the premises of a facility under the jurisdiction of the Commission is
forbidden:
(a) Aminoimidazole carboxamide
ribonucleotide (AICAR);
(b)
Darbepoetin;
(c) Equine Growth
Hormone;
(d)
Erythropoietin;
(e) Hemopure
®;
(f) Myo-Inositol
Trispyprophosphate (ITPP);
(g)
Oxyglobin®;
(h) Thymosin
beta;
(i) Venoms or derivatives
thereof;
(j) Thymosin
beta.
(4) The use of
Extracorporeal Shock Wave Therapy or Radial Pulse Wave Therapy shall not be
permitted unless the following conditions are met:
(a) Any Extracorporeal Shock Wave Therapy or
Radial Pulse Wave Therapy machine, whether in operating condition or not, must
be registered with and approved by the Commission or its designee before such
machine is brought to or possessed on any racetrack or training center within
the jurisdiction of the Commission;
(b) The use of Extracorporeal Shock Wave
Therapy or Radial Pulse Wave Therapy within the jurisdiction:
1. shall be limited to veterinarians licensed
to practice by the Commission;
2.
may only be performed with machines that are registered and approved for use by
the Commission; and
3. used at a
previously-disclosed location that is approved by the Commission must be
reported within 24 hours prior to treatment on the prescribed form to the
official veterinarian.
(c) Any treated horse shall not be permitted
to race or breeze for a minimum of ten days following treatment;
(d) Any horse treated with Extracorporeal
Shock Wave Therapy or Radial Pulse Wave Therapy shall be added to a list of
ineligible horses. This list shall be kept in the race office and accessible to
the jockeys and/or their agents during normal business hours and be made
available to other regulatory jurisdictions.
(e) A horse that receives any such treatment
without full compliance with 205 CMR 3.28(4) and similar rules in any other
jurisdiction in which the horse was treated shall be placed on the Steward's
List.
(f) Any person participating
in the use of ESWT and/or the possession of ESWT machines in violation of this
rule shall be considered to have committed a Prohibited Practice and is subject
to a Class A Penalty.
(5)
The use of a nasogastric tube (a tube longer than six inches) for the
administration of any substance within 24 hours prior to the post time of the
race in which the horse is entered is prohibited without the prior permission
of the official veterinarian or his or her designee.
Annex I
Prohibited Substances and Prohibited Methods
Prohibited Substances
All substances in the following categories shall be strictly
prohibited unless otherwise provided in accordance with
205 CMR
4.00: Rules of Horse Racing. Any
reference to substances in 205 CMR 3.28(5) does not alter the requirements for
testing concentrations in race day samples. Nothing in this list shall alter
the requirements of post-race testing.
(a)
Non-approved
Substances. Any pharmacologic substance that is not approved by
any governmental regulatory health authority for human or veterinary use within
the jurisdiction is prohibited. This prohibition includes drugs under
pre-clinical or clinical development, discontinued drugs, and designer drugs (a
synthetic analog of a drug that has been altered in a manner that may reduce
its detection) but does not include vitamins, herbs and supplements for
nutritional purposes that do not contain any other prohibited substance, or the
administration of a substance with the prior approval of the Commission in a
clinical trial for which an FDA or similar exemption has been
obtained.
(b)
Anabolic
Agents. Anabolic agents are prohibited.
1.
Anabolic Androgenic Steroids
(AAS).
1.1. Exogenous AAS,
including:
1-androstenediol
(5[ALPHA]-androst-1-ene-3[BETA],17[BETA]-diol); 1-androstenedione
(5[ALPHA]-androst-1-ene-3,17-dione); bolandiol
(estr-4-ene-3[BETA],17[BETA]-diol); bolasterone; boldenone; boldione
(androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol
([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17[ALPHA]-ol);
dehydrochlormethyltestosterone
(4-chloro-17[BETA]-hydroxy-17[ALPHA]-methylandrosta-1,4-dien-3-one);
desoxymethyltestosterone (17[ALPHA] -methyl-5[ALPHA]-androst-2-en-
17[BETA]-ol); drostanolone; ethylestrenol (19-norpregna-4-en-17[ALPHA]-ol);
fluoxymesterone; formebolone; furazabol (17[ALPHA]-
methyl[1,2,5]oxadiazolo[3',4':2,3]-5[ALPHA]-androstan-17[BETA]-ol); gestrinone;
4- hydroxytestosterone (4,17[BETA]-dihydroxyandrost-4-en-3-one); mestanolone;
mesterolone; metandienone
(17[BETA]-hydroxy-17[ALPHA]-methylandrosta-1,4-dien-3-one); metenolone;
methandriol; methasterone (17[BETA]-hydroxy-2[ALPHA],17[ALPHA]-
dimethyl-5[ALPHA]-androstan-3-one); methyldienolone
(17[BETA]-hydroxy-17[ALPHA]-methylestra-4,9-dien-3-one); methyl-1-testosterone
(17[BETA]-hydroxy-17[ALPHA]-methyl-5[ALPHA]-androst-1-en-3-one);
methylnortestosterone (17P-hydroxy-17[ALPHA]-methylestr-4-en-3-one);
methyltestosterone; metribolone (methyltrienolone,
17[BETA]-hydroxy-17[ALPHA]-methylestra-4,9,11-trien-3-one); mibolerone;
nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone;
norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone;
oxymetholone; prostanozol
(17[BETA]-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5[ALPHA]-androstane);
quinbolone; stanozolol; stenbolone; 1-testosterone
(17[BETA]-hydroxy-5[ALPHA]-androst-1 -en-3-one); tetrahydrogestrinone
(17-hydroxy-18a-homo-19-nor- 17[ALPHA]-pregna-4,9,11-trien-3-one); trenbolone
(17[BETA]-hydroxyestr- 4,9,11-trien-3-one); and other substances with a similar
chemical structure or similar biological effect(s).
1.2. Endogenous AAS or their synthetic esters
when administered exogenously: androstenediol (androst-5-ene-3[BETA],
17[BETA]-diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone
(17[BETA]-hydroxy-5[ALPHA]-androstan-3-one); prasterone
(dehydroepiandrosterone, DHEA, 3[BETA]-hydroxyandrost-5-en-17-one);
testosterone; and their metabolites and isomers including, but not limited to:
5[ALPHA]-androstane-3[ALPHA], 17[ALPHA]-diol; 5[ALPHA]-androstane-3[ALPHA],
17P-diol; 5[ALPHA]-androstane-3[BETA], 17[ALPHA]-diol;
5[ALPHA]-androstane-3[BETA], 17[BETA]-diol; 5p-androstane-3[ALPHA],
17[BETA]-diol, androst-4-ene-3[ALPHA], 17[ALPHA]-diol; androst-4-ene-3[ALPHA],
17[BETA]-diol; androst-4-ene-3p, 17[ALPHA]-diol; androst-5-ene-3[ALPHA],
17[ALPHA]-diol; androst-5-ene-3[ALPHA], 17[BETA]-diol; androst-5-ene-3[BETA],
17[ALPHA]-diol; 4-androstenediol (androst-4-ene-3[BETA], 17[BETA]-diol);
5-androstenedione (androst-5- ene-3,17-dione); androsterone (3 [BETA]-hydroxy-5
[ALPHA] - androstan-17-one); epi-dihydrotestosterone; epitestosterone;
etiocholanolone; 7[ALPHA]-hydroxy-DHEA; 7[BETA]-hydroxy-DHEA; 7-keto-DHEA;
19-norandrosterone; 19-noretiocholanolone.
(c)
Other Anabolic Agents,
Including, but Not Limited to: Clenbuterol, selective androgen
receptor modulators (SARMs e.g., andarine and ostarine),
ractopamine, tibolone, zeranol, zilpaterol.
(d)
Peptide Hormones, Growth
Factors and Related Substances. The following substances, and
other substances with similar chemical structure or similar biological
effect(s), are prohibited:
1.
Erythropoietin-Receptor agonists: Erythropoiesis-Stimulating Agents (ESAs)
including, e.g., darbepoetin (dEPO); erythropoietins (EPO);
EPO-Fc; EPO-mimetic peptides (EMP), e.g., CNTO 530 and
peginesatide; and methoxypolyethylene glycol-epoetin beta (CERA); and
Non-erythropoietic EPO-Receptor agonists, e.g., ARA-290,
asialo EPO and carbamylated EPO;
2.
Hypoxia-inducible factor (HIF) stabilizers, e.g., cobalt (when
found in excess of regulatory authority limits) and roxadustat (FG-4592); and
HIF activators, (e.g., argon, xenon);
3. Chorionic Gonadotropin (CG) and
Luteinizing Hormone (LH) and their releasing factors, in males;
4. Corticotrophins and their releasing
factors;
5. Growth Hormone (GH) and
its releasing factors including Growth Hormone Releasing Hormone (GHRH) and its
analogues, e.g., CJC-1295, sermorelin and tesamorelin; Growth
Hormone Secretagogues (GHS), e.g., ghrelin and ghrelin
mimetics, e.g., anamorelin and ipamorelin; and GH-Releasing
Peptides (GHRPs), e.g., alexamorelin, GHRP-6, hexarelin and
pralmorelin (GHRP-2);
6. Venoms and
toxins including, but not limited to, venoms and toxins from sources such as
snails, snakes, frogs, and bees as well as their synthetic analogues such as
ziconotide.
7. In addition, the
following growth factors are prohibited: Fibroblast Growth Factors (FGFs),
Hepatocyte Growth Factor (HGF), Insulin-like Growth Factor-1 (IGF-1) and its
analogues, Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor
(PDGF), Vascular-Endothelial Growth Factor (VEGF) and any other growth factor
affecting muscle, tendon or ligament protein synthesis/degradation,
vascularization, energy utilization, regenerative capacity or fiber type
switching.
(e)
Beta-2 Agonists. All beta-2 agonists, including all
optical isomers (i.e.,d- and 1-) where relevant, are
prohibited.
(f)
Hormone
and Metabolic Modulators. The following are prohibited:
1. Aromatase inhibitors including, but not
limited to: aminoglutethimide, anastrozole, androsta-l,4,6-triene-3,17-dione
(androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane,
formestane, letrozole, testolactone;
2. Selective estrogen receptor modulators
(SERMs) including, but not limited to: raloxifene, tamoxifen,
toremifene;
3. Other
anti-estrogenic substances including, but not limited to: clomiphene,
cyclofenil, fulvestrant;
4. Agents
modifying myostatin function(s) including, but not limited to: myostatin
inhibitors;
5. Metabolic
modulators:
5.1. Activators of the
AMP-activated protein kinase (AMPK), e.g., AICAR, and
Peroxisome Proliferator Activated Receptor [DELTA] (PPAR[DELTA]) agonists
(e.g., GW 1516);
5.2. Insulins;
5.3. Trimetazidine; and
5.4. Thyroxine and thyroid
modulators/hormones including, but not limited to, those containing T4
(tetraiodothyronine/thyroxine), T3 (triiodothyronine), or combinations thereof.
(g)
Diuretics and Other Masking Agents. The following
diuretics and masking agents are prohibited, as are other substances with
similar chemical structure or similar biological effect(s): acetazolamide,
amiloride, bumetanide, canrenone, chlorthalidone, desmorpressin, etacrynic
acid, indapamide, metolazone, plasma expanders (
e.g.,
glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch
and mannitol), probenecid, spironolactone, thiazides (
e.g.,
bendroflumethiazide, chlorothiazide, hydrochlorothiazide), torsemide,
triamterene, and vasopressin receptor antagonists or vaptans
(
e.g., tolvaptan).
Furosemide and trichlormethiazide may be administered only in a
manner permitted by other rules of the Commission.
Prohibited Methods
(6)
Manipulation of Blood and
Blood Components. The following are prohibited:
(a) The administration or reintroduction of
any quantity of autologous, allogenic (homologous) or heterologous blood or red
blood cell products of any origin into the circulatory system.
(b) Artificially enhancing the uptake,
transport or delivery of oxygen including, but not limited to:
perfluorochemicals, efaproxiral (RSR13) and modified hemoglobin products
(e.g., hemoglobin-based blood substitutes, microencapsulated
hemoglobin products), excluding supplemental oxygen.
(c) Any form of intravascular manipulation of
the blood or blood components by physical or chemical means.
(7)
Chemical and
Physical Manipulation. Tampering, or attempting to tamper, in
order to alter the integrity and validity of samples collected by the
Commission, is prohibited. These methods include, but are not limited to, urine
substitution or adulteration (e.g., proteases).
(8)
Gene Doping. The
following, with the potential to enhance sport performance, are prohibited:
(a) The transfer of polymers of nucleic acids
or nucleic acid analogues.
(b) The
use of normal or genetically modified hematopoietic cells.
Click to view
image
